Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes.
Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, Kubonishi S, Morita Y, Nakashima Y, Onodera K, Suzuki K, Suzuki T, Tamai Y, Usuki K, Yokota A, Yonaga H, Hayakawa J, Midorikawa S, Nishio M, Suda M, Matsue K. Kosugi H, et al. Among authors: fujisaki t. Int J Hematol. 2024 Nov 21. doi: 10.1007/s12185-024-03872-3. Online ahead of print. Int J Hematol. 2024. PMID: 39572468
Clinical outcomes of patients from older community hospitalized for heart failure in guideline-directed medical therapy era: Insights from the COMPASS-HF registry.
Sueta D, Araki S, Usuku H, Fujisaki T, Kiyama T, Ishii M, Tabata N, Fujisue K, Kusaka H, Hanatani S, Yamamoto E, Haruguchi H, Takamori H, Tsujita K. Sueta D, et al. Among authors: fujisaki t. J Cardiol. 2024 Sep 17:S0914-5087(24)00178-3. doi: 10.1016/j.jjcc.2024.09.006. Online ahead of print. J Cardiol. 2024. PMID: 39299602
Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.
Shimoda K, Komatsu N, Matsumura I, Ikeda K, Hino M, Hidaka M, Maeda Y, Kondo T, Fujisaki T, Shoshi K, Azuma K, Fukushima R, Kawashima J, Kosugi H. Shimoda K, et al. Among authors: fujisaki t. Int J Hematol. 2024 Sep;120(3):314-324. doi: 10.1007/s12185-024-03822-z. Epub 2024 Aug 7. Int J Hematol. 2024. PMID: 39110143 Free PMC article. Clinical Trial.
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balarí AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Hungria V, et al. Among authors: fujisaki t. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1. N Engl J Med. 2024. PMID: 38828933 Clinical Trial.
252 results